Back to Newsroom

Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer’s Disease

BROOMFIELD, Colo., July 14, 2015 /PRNewswire/ – Accera, Inc. today announced that it has achieved 75% enrollment for its NOURISH AD Phase 3 clinical study of AC-1204 for the treatment of Alzheimer’s disease. The study has a total planned enrollment of approximately 480 patients and is the first of two Phase 3 trials of AC-1204, an investigational new drug designed to address the metabolic defect of the brain observed in Alzheimer’s patients.

Click here to read more